

Context-specific inhibition of mitochondrial ribosomes by phenicol and oxazolidinone antibiotics

Brianna Bibel ¹, Tushar Raskar ^{2,3}, Mary Couvillion ⁴, Muhoon Lee ⁵, Jordan I. Kleinman ¹, Nono Takeuchi-Tomita ⁵, L. Stirling Churchman ⁴, James S. Fraser ^{2,3}, Danica Galonić Fujimori ^{1,3,6,*}


¹Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94143, United States
²Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA 94143, United States
³Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94143, United States
⁴Department of Genetics, Harvard Medical School, Boston, MA 02115, United States
⁵Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 5-1-5, Kashiwanoha, Kashiwa-shi, Chiba 277-8562, Japan
⁶Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94143, United States

*To whom correspondence should be addressed. Email: Danica.Fujimori@ucsf.edu

Abstract

The antibiotics chloramphenicol (CHL) and oxazolidinones, including linezolid (LZD), are known to inhibit mitochondrial translation. This can result in serious, potentially deadly, side effects when used therapeutically. Although the mechanism by which CHL and LZD inhibit bacterial ribosomes has been elucidated in detail, their mechanism of action against mitochondrial ribosomes has yet to be explored. CHL and oxazolidinones bind to the ribosomal peptidyl transfer center (PTC) of the bacterial ribosome and prevent incorporation of incoming amino acids under specific sequence contexts, causing ribosomes to stall only at certain sequences. Through mitoribosome profiling, we show that inhibition of mitochondrial ribosomes is similarly context-specific—CHL and LZD lead to mitoribosome stalling primarily when there is an alanine, serine, or threonine in the penultimate position of the nascent peptide chain. We further validate context-specific stalling through *in vitro* translation assays. A high-resolution cryo-electron microscopy structure of LZD bound to the PTC of the human mitoribosome shows extensive similarity to the mode of bacterial inhibition and also suggests potential avenues for altering selectivity. Our findings could help inform the rational development of future, less mitotoxic, antibiotics, which are critically needed in the current era of increasing antimicrobial resistance.

Graphical abstract



Introduction

Bacteria are acquiring resistance to mainstay antibiotics at an alarming rate, necessitating the development of novel compounds [1]. Oxazolidinones, including the FDA-approved

linezolid (Zyvox) and tedizolid (Sivextro), are a recently introduced class of synthetic antibiotics that show activity against multiple drug-resistant pathogens. Unfortunately, like several other antibiotics designed to target bacterial ribosomes,

Received: October 7, 2024. Revised: January 6, 2025. Editorial Decision: January 13, 2025. Accepted: January 17, 2025

© The Author(s) 2025. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License

(<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

including the phenicol antibiotic chloramphenicol (CHL), oxazolidinones can cause mitochondrial toxicity thought to be due to off-target inhibition of mitochondrial ribosomes (mitoribosomes) [2]. Mitoribosomes translate 13 proteins (from 11 transcripts), all of which are crucial components of the mitochondrial electron transport chain. Inhibition of mitochondrial translation has thus been implicated in lactic acidosis, myelosuppression, peripheral neuropathy, and other serious, sometimes life-threatening, complications [3–5]. These restrict the use of oxazolidinones and, along with growing resistance, fuel an active search for less mitotoxic alternatives. Mitoribosomes are susceptible to phenicol- and oxazolidinone-mediated inhibition due to their structural similarity to bacterial ribosomes [6]; however, the extent to which the mechanisms of binding and inhibition are conserved is unknown.

Structural and biochemical studies have elucidated the basis of bacterial ribosomal inhibition by phenicols and oxazolidinones [7–10]. Oxazolidinones and phenicols bind to the A-site of bacterial ribosomes' peptidyl transfer center (PTC) [11]. These antibiotics were previously thought to inhibit translation globally by preventing accommodation of the A-site transfer RNA (tRNA) [8]; however, it was recently discovered that CHL and linezolid (LZD) instead act as context-dependent inhibitors of bacterial translation. More specifically, LZD and CHL cause preferential stalling during the translation of specific nascent peptides, chiefly when an alanine (Ala), and to a lesser extent serine (Ser) or threonine (Thr), residue is in the penultimate position of the nascent chain (–1 with respect to the P site, or $P - 1$) [7]. We and others recently showed that this context dependency is due to steric constraints of the antibiotic-bound ribosome and stabilizing CH– π interaction between the alanine's methyl group and the aryl ring of the oxazolidinone or phenicol (Fig. 1A) [9, 10]. Analogous interactions via Ser and Thr's side chains similarly stabilize antibiotic binding in the bacterial ribosome [9], leading to the secondary Ser/Thr bias, which is more pronounced for CHL than LZD [7].

Due to the endosymbiotic origins of mitochondria, the PTC is well conserved between bacterial and mitochondrial ribosomes [12]. Accordingly, mitoribosomes are susceptible to inhibition by CHL, LZD, and other oxazolidinones [13]. The ability of CHL to inhibit mitochondrial translation has long been known—it has led to its broad disuse as an oral antibiotic, in parallel with its broad use as an experimental tool to block mitochondrial translation in a laboratory setting. Multiple studies have found that oxazolidinones inhibit mitochondrial translation as well [13, 14]. Despite these functional data, no structures of phenicol- or oxazolidinone-bound mitoribosomes are available, although cross-linking data have identified a binding site of LZD on the mitoribosome analogous to that of the bacterial ribosome [6]. Thus, the precise binding mode of CHL and oxazolidinones to mitoribosomes remains unknown. Furthermore, it is yet to be elucidated whether these antibiotics act as global inhibitors of translation or whether inhibition happens in a nascent peptide-dependent manner at the mitoribosome.

Here, using a combination of mitoribosome profiling, *in vitro* translation assays, and cryo-electron microscopy (cryo-EM), we characterize the mechanism by which CHL and LZD inhibit mitochondrial ribosomes. Through mitoribosome profiling in human cells, we discover that CHL and LZD do indeed inhibit mitoribosomal translation in a context-

dependent manner. We find that, in the presence of these antibiotics, mitoribosomes stall mainly on sequences where there is an alanine (or to a lesser extent serine or threonine) in the penultimate position of the nascent chain, similar to the preference seen in bacterial translation inhibition. We confirm the differential and sequence-dependent nature of such stalling in a fully reconstituted mammalian mitochondrial translation system. Finally, to investigate a potential structural basis for such inhibition, we solve the structure of the large (39S) subunit (LSU) of a human mitoribosome bound to LZD. This structure shows a binding site and binding interactions that are largely well conserved to those of bacterial ribosomes. However, it also reveals an altered LZD C5 tail conformation and an extended water network that is absent in bacterial ribosomes. Together, these results imply that, while the structural basis for the inhibition of mammalian mitoribosomes by LZD is similar to that of bacterial ribosomes, distinct features of its binding to mitoribosomes suggest the potential for the design of next-generation oxazolidinone antibiotics with lower mitochondrial toxicity.

Materials and methods

Mitoribosome profiling

Cell culture and treatment

FreeStyle™ 293-F cells (HEK293 cells adapted for serum-free suspension culture) were grown in suspension culture at 37°C, 5% CO₂, with orbital shaking (115 rpm) in unmodified FreeStyle™ 293 Expression Medium (Gibco) in the absence of antibiotics. Cell cultures were diluted to 2×10^6 viable cells/ml and 50 ml portions were transferred into 125 ml flasks before use. To each portion, DMSO or antibiotic was added to a final concentration of 1% DMSO, 300 μ M (97 μ g/ml) CHL, 300 μ M (101 μ g/ml) LZD, or 100 μ M (155 μ g/ml) RET. Samples were placed back into the incubator for 5 min before collecting cells via fast vacuum filtration through a 0.8 μ m filter. The collected cells were then quickly scraped off the filter and plunged into liquid nitrogen. The frozen cells were stored at –80°C until use.

Mitoribosome footprint isolation

Mitoribosome footprints were prepared as described [15] with modifications. Each 10×10^6 cell pellet of frozen cells was resuspended in 900 μ l of mito-RP lysis buffer (10 mM Tris, pH 7.5, 50 mM NH₄Cl, 20 mM MgCl₂, 0.25% lauryl maltoside, 10 mM DTT, 1 $\times$ EDTA-free protease inhibitor cocktail (Pierce) containing antibiotic or DMSO at the same concentration as in the pretreatment) and incubated for 10 min on ice. It was then homogenized via 15 strokes of a Dounce homogenizer and centrifuged for 1 min @ 1000 $\times$ g. RNase If (NEB) was added to each supernatant for a final concentration of 7.25 U/ μ l to produce mitoribosome footprints. Samples were incubated for 30 min at room temperature without rotation. Eighty units of SUPERaseIn™ RNase Inhibitor (Invitrogen) was then added per 450 μ l of digested lysate to prevent overdigestion and the digested lysate was clarified by centrifugation in a benchtop microcentrifuge @ 10 000 rpm, 5 min, 4°C. Clarified lysates were then transferred to a 10%–50% linear sucrose gradient (prepared in mito-RP lysis buffer without lauryl maltoside and protease inhibitor, using a BioComp Gradient Master™) and centrifuged for 3 h @ 4°C in an SW41 Ti rotor in order to separate mitomonosomes, cytosolic




Figure 1. LZD and CHL alter the distribution of ribosomes along each mitochondrial transcript without altering overall coverage. **(A)** Chemical structures of CHL and LZD. **(B)** Per-codon reads per million (RPM) counts for mitoribosome-protected fragments for protein-coding genes across the mitochondrial genome. One representative replicate is shown for each sample. **(C)** Relative ribosome coverage across each open reading frame, expressed as transcripts per million (TPM) in cells treated with CHL, LZD, retapamulin (RET), or dimethyl sulfoxide (DMSO). Error bars indicate standard deviation across replicates. **(D)** Mitochondrial transcriptome-wide frequency of per-codon RPM in each treatment condition. Data from all replicates are included.

monosomes, and polysomes based on their differential densities and thus sedimentation rates. Fractions were collected with a BioComp Piston Gradient FractionatorTM and portions corresponding to mitomonosomes (identified based on UV 260 trace and confirmed via western blot for MRPL12 and MRPS18B) were frozen @ -80°C in 3 volumes of TRIzolTM LS (Invitrogen). Footprints were then isolated using a Direct-zolTM RNA kit (Zymo) and subsequently concentrated using a RNA Clean & Concentrator-5 kit (Zymo). RNA was then size-selected by running a 15% TBE-urea gel and extracting fragments between 28 and 40 nt in length, corresponding to mitoribosome-protected footprints. DMSO: $n = 4$ biological replicates (separate cell cultures); CHL: $n = 4$ biological replicates and 1 technical replicate (separate datasets from same

culture); LZD: $n = 4$ biological replicates and 2 technical replicates; RET: $n = 2$ biological replicates.

Sequencing library preparation

Libraries were prepared from the extracted footprint RNA as described [16–19] with modifications. Briefly, extracted RNA was desalted using a RNA Clean & Concentrator-5 kit (Zymo), then dephosphorylated with T4 PNK (NEB) and ligated to a pread-enylated oligonucleotide linker (NI-816: 5′-/5Phos /NNNNNTAGACAGATCGGAAGAGCACACGTCTGAA /3ddC/-3′) using T4 RNA Ligase 2 truncated KQ (NEB). Unligated linker was depleted by treatment with yeast 5′-deadenylase (NEB) and RecJ exonucle-

ase (Lucigen/Epicenter), and the linker-ligated footprints were then purified via a Oligo Clean and Concentrator kit (Zymo). The ligation products were then reverse transcribed using Protoscript II reverse transcriptase (NEB) and NI-802 primer (5'-/5Phos/NNAGATCGGAAGAGCGTCGTGTAGGGAAAGAG/iSp18/GTGACTGGAGTTCAGACGTGTGCTC-3'). The RNA template was then hydrolyzed with NaOH. The reverse transcription products were desalted and concentrated with an Oligo Clean & Concentrator kit (Zymo), followed by gel purification via a 15% TBE-urea polyacrylamide gel electrophoresis (PAGE). Extracted complementary DNA was then circularized using CircLigase II (Lucigen). Circular DNA was quantified via quantitative polymerase chain reaction (PCR), and then amplified via PCR with the forward primer NI-798 5'-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTC-3' and a unique reverse indexing primer (containing a unique 6-nt barcode) for each sample. PCR products were then purified via a DNA Clean & Concentrator-5 column (Zymo) followed by gel purification via an 8% non-denaturing TBE PAGE gel. Extracted DNA was then quantified and checked for quality with a BioAnalyzer (Agilent).

RNA sequencing

Equimolar concentrations of all samples were pooled and sequencing was performed by the UCSF Center for Advanced Technology on an Illumina HiSeq 4000 (SE65 66 × 8 × 8 × 0).

Mitoribosome profiling data analysis

Mitoribosome profiling data were processed as described in [20]. Briefly, reads in the size range 33–39 nt were used and ribosome A-site ($P + 1$) location was assigned using offsets from the 3' end of 33:[−15], 34:[−16], 35:[−17], 36:[−17], 37:[−18], 38:[−19], and 39:[−20]. All other ribosome sites (e.g. P , $P - 1$) were implicit in this transformation. Coverage across each codon was calculated by summing the read counts across the three subcodon positions and counts were normalized to reads per million mitochondrial mRNA-mapped reads. Relative synthesis of mitochondrial gene products was determined using Rsubread featureCounts [21] as described in [15]. All read sizes were used and values were normalized by Open Reading Frame (ORF) length and total transcript counts (TPM).

Predictive information at each ribosomal position (e.g. $P - 1$, P , $P + 1$, etc.) was calculated from the percentage of reads with each amino acid in each position. First, data from plots like that in Fig. 1C were collected for all ribosomal positions $P - 6$ to $P + 8$. For each, the absolute difference between the percentage of reads in the treatment condition and in DMSO was taken for all amino acids and summed. Next, the value at $P + 8$, where there should be no contribution to pausing, was taken as background and set as zero. Finally, total predictive information across these 15 positions was set to 100% and each expressed as a percentage.

Relative ribosome occupancies for codons (as in Fig. 2C) were computed by taking the ratio of the transformed ribosome density in a 3-nt window at the codon over the overall density in the respective coding sequence. For each codon, the values of all occurrences across the genome were averaged.

Pause scores were calculated as the fold change over the mean of rpm-normalized values in a 21-nt sliding window. A pause was called on a codon if the pause score was >2 in

all replicates. Pausing peptide motifs were created with the kpLogo [22] web app (<http://kplogo.wi.mit.edu/>), used with default parameters (unweighted, background probability calculated by averaging across all positions). Probability logos are shown, in which residues are scaled relative to the statistical significance determined by one-sided binomial tests [$-\log_{10}(P \text{ value})$] of each residue at each position. Enriched residues stack on the top, whereas depleted residues stack on the bottom.

Processing and analysis scripts are available at Zenodo under DOI 10.5281/zenodo.14590510 [23]; an add-on to DOI: 10.5281/zenodo.6814724 [24].

Reconstituted mitochondrial *in vitro* translation assay

Preparation of aminoacylated tRNA mixture

The aminoacylated iVT tRNA_{mix} included 12 iVT tRNA species (Supplementary Table S2). To prepare the aminoacylated iVT tRNA_{mix}, each iVT tRNA species (0.0019 A₂₆₀ units) was first aminoacylated using the cognate charging enzyme and amino acid individually. Thereafter, all aminoacylated iVT tRNAs were combined and subjected to one NAP-5 column, as described [25]. IVT yeast tRNAs, except tRNA^{Lys}, were aminoacylated using yeast S100 extracts. Yeast iVT tRNA^{Lys} was aminoacylated utilizing the recombinant *Escherichia coli* lysyl-tRNA synthetase. IVT mt-tRNA^{Met}, mt-tRNA^{Leu}, and mt-tRNA^{Ser} were aminoacylated by the cognate recombinant mitochondrial aminoacyl-tRNA synthetase, respectively. IVT mt-tRNA^{Phe} was aminoacylated utilizing the recombinant *E. coli* phenylalanyl-tRNA synthetase.

In vitro translation

In vitro translation using a reconstituted mammalian mitochondrial translation system was performed as described [26]. Briefly, the translation mixtures (5 µl) contained 50 mM HEPES-KOH (pH 7.5), 100 mM potassium glutamate, 11 mM Mg(OAc)₂, 0.1 mM spermine, 1 mM DTT, 0.15 mM of each amino acid (except methionine and cysteine), 0.05 mM methionine, 0.1 mM cysteine, 1 mM ATP, 1 mM GTP, 20 mM creatine phosphate, 0.1 µg 10-formyl-5,6,7,8-tetrahydrofolic acid, 100 nM creatine kinase, 20 nM myokinase, 15 nM nucleoside diphosphate kinase, 15 nM pyrophosphatase, 0.5 µM IF-2mt, 1.0 µM IF-3mt, 5 µM EF-Tumt, 1 µM EF-Tsmt, 0.5 µM EF-G1mt, 0.5 µM EF-G2mt, 0.5 µM RF-1Lmt, 0.5 µM RRFmt, 5 µM methionyl-tRNA transformylase (*E. coli* MTF), 0.2 µM 55S ribosome, aminoacyl-tRNA mixture (0.045 A₂₆₀ units iVT tRNA_{mix}), 0.2 µM mRNA (Supplementary Table S1), 0.06 µg/µl IgBiT, and indicated concentration of antibiotics. The reaction mixture was incubated at 37°C for 30 min. The nanoluciferase (nLuc) activities were analyzed using 2 µl of sample as described [26]. Under these conditions, the nLuc activities were detected in a linear range over time, and depended on the concentration of the mRNA. IC₅₀ values were determined using nonlinear regression in GraphPad Prism.

Mitoribosome structural analysis

Human 55S mitomonosomes were purified from LZD-treated FreeStyle™ 293-F cells using a modification of [27, 28], as described below.




Figure 2. Mitribosome profiling reveals a strong A/S/T bias in the $P - 1$ position of cells treated with LZD or CHL. **(A)** Predictive information of each codon position of mitribosome footprints with respect to the ribosomal P site. Predictive information was calculated from the percentages of reads with each amino acid in each position as in panel (B) (see the ‘Materials and methods’ section). **(B)** Percentage of mitribosome footprint reads with codons for each amino acid in the $P - 1$ position. Error bars indicate standard deviation across replicates. Asterisks indicate a statistically significant difference compared to DMSO (Student’s t -test, $P < .05$). **(C)** Mean codon occupancy (see the ‘Materials and methods’ section) versus DMSO control at the $P - 1$ site in each treatment condition. Each codon must be present at least four times in the transcriptome to be included. **(D)** Percentage of mitribosome footprint reads with codons for glycine in the $P - 1$, P , and $P + 1$ positions, as in panel (B). Error bars indicate standard deviation across replicates. LZD, linezolid; CHL, chloramphenicol; DMSO, dimethyl sulfoxide.

Cell culture and harvesting

FreeStyle™ 293-F cells (Gibco) were grown in suspension culture at 37°C, 5% CO₂, with orbital shaking (115 rpm), in unmodified FreeStyle™ 293 Expression Medium (Gibco) in the absence of antibiotics. In total, mitomonosomes from 4 l of cells were purified and combined (from 2, 2 l purifications) for cryo-EM sample preparation. For each 2 l preparation, cultures were scaled up to 2 l (in 4 × 500 ml portions in 2 l flasks) and grown to a final density of $\sim 3 \times 10^6$ cells/ml. At that time, cells were treated with a brief (5 min) high concentration of LZD (100 µg/ml) (300 µM). Cultures were then harvested by centrifugation at $1000 \times g$ for 7 min, 4°C. The supernatant was decanted and the pelleted cells were washed to remove excess media by resuspension in ice-cold PBS containing a lower concentration of LZD (50 µg/ml) (150 µM) and EDTA-free protease inhibitor (Pierce). The resuspended cells were centrifuged at $1200 \times g$ for 10 min, 4°C, after which the supernatant was decanted. The pellets were then weighed and flash frozen in liquid nitrogen before storing at –80°C until use.

Mitochondrial purification

Mitochondria from 2 l worth of FreeStyle™ 293-F cells were purified at a time. LZD was maintained in all purification buffers at a concentration of 50 µg/ml (150 µM). Pellets were thawed on ice and resuspended in 60 ml ice-cold MIB buffer [50 mM HEPES–KOH, pH 7.4, 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, EDTA-free protease inhibitor (Pierce), 50 µg/ml LZD]. The resuspended cells were then incubated at 4°C for 15 min with gentle agitation on a nutator. Twenty milliliters of SM4 [280 mM sucrose, 840 mM mannitol, 50 mM HEPES–KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, EDTA-free protease inhibitor (Pierce), 50 µg/ml LZD], equivalent to one-third of the MIB buffer volume, was then added and the sample was homogenized via 60 strokes of a Dounce homogenizer (processed in two portions in a 100 ml Dounce). Differential centrifugation was then performed to fractionate the subcellular organelles as described [27], but with the inclusion of 50 µg/ml LZD (150 µM) in all buffers. Briefly, the homogenized sample was centrifuged at $800 \times g$ for 15 min, 4°C, and the supernatant was filtered through Miracloth. The remaining pellet was resuspended in 20 ml MIBSM buffer (consisting of a 3:1 ratio of MIB:SM4), homogenized by 15 strokes of the Dounce, and centrifuged for 15 min @ $800 \times g$, 4°C. The resultant supernatant was passed through Miracloth and combined with the previous supernatant. The combined supernatants were then centrifuged at $1000 \times g$ for 15 min, 4°C. The supernatant from this was then centrifuged for 15 min at $10\,000 \times g$, 4°C. The resultant supernatant and loose pellet were carefully removed, keeping the tight pellet, containing mitochondria. This tight pellet was then resuspended in 10 ml MIBSM buffer containing 100 U of TURBO™ DNase (Invitrogen) per 10 g of cells, and incubated with gentle agitation at 4°C for 20 min. It was then centrifuged at $10\,000 \times g$ for 15 min, 4°C, before resuspending in 2 ml SEH buffer (250 mM sucrose, 1 mM EDTA, 20 mM HEPES–KOH, pH 7.4, 50 µg/ml LZD) and homogenizing gently with 5 strokes of a Dounce homogenizer. The sample was then loaded onto a chilled 15%–23%–32%–60% sucrose gradient (prepared in 50 mM HEPES–KOH, pH 7.4, 2.5 mM EDTA, 50 µg/ml LZD) and centrifuged in an SW41 ro-

tor at 28 500 rpm. The brown band at the 32%–60% interface (containing crude mitochondria) was then collected, flash frozen in liquid nitrogen, and stored at –80°C until use.

Mitoribosome purification

Frozen mitochondria were thawed on ice and resuspended in 2 volumes of mitochondrial lysis buffer [25 mM HEPES–KOH, pH 7.4, 150 mM KCl, 50 mM MgOAc, 2% Triton (v/v) X-100, 2 mM DTT, EDTA-free protease inhibitor (Pierce), 50 µg/ml LZD] and mixed via inversion, followed by homogenization with 5 strokes of a Dounce homogenizer. The sample was then rotated on a nutator at 4°C to complete the lysis. The lysed sample was then clarified by centrifugation at $30\,000 \times g$, 4°C, for 20 min in a TLA 100.3. The supernatant was carefully removed and the pellet discarded. This centrifugation step was then repeated to ensure clarification. The clarified mitochondrial lysate was then loaded onto a sucrose cushion [1 M sucrose (34%, w/v); 20 mM HEPES–KOH, pH 7.4, 100 mM KCl, 20 mM Mg(OAc)₂, 1% (v/v) Triton X-100, 2 mM DTT, 50 µg/ml LZD] in a 2.5:1 ratio of lysate to sucrose cushion. The samples were then centrifuged at $\sim 231\,550 \times g$ in a TLA 100.3 rotor (66 000 rpm) to pellet the mitoribosomes. The supernatant was discarded and the pellets rinsed gently several times with resuspension buffer (50 mM HEPES–KOH, pH 7.4, 250 mM KCl, 12.5 mM Mg(OAc)₂, 5 mM DTT, 50 µg/ml LZD). The pellets were then resuspended in a total of 170 µl of resuspension buffer and loaded onto a 15%–30% sucrose gradient (prepared in resuspension buffer using a BioComp Gradient Master™) to isolate mitomonosomes. The samples were centrifuged at 19 500 rpm for 18.5 h in an SW41 rotor. The gradient was then fractionated using a BioComp Piston Gradient Fractionator™ with UV260 monitoring. Two hundred microliter fractions were collected and the fraction corresponding to the 55S peak was collected and used for cryo-EM sample preparation.

Cryo-EM sample preparation

Purified mitomonosomes were concentrated using a 100-kDa Amicon® Ultra centrifugal filter, followed by exchange with resuspension buffer (50 mM HEPES–KOH, pH 7.4, 250 mM KCl, 12.5 mM Mg(OAc)₂, 5 mM DTT, 50 µg/ml LZD). The final concentration of the sample was calculated assuming that $1 A_{260} = 0.1$ mg/ml [29]. Quantifoil R 1.2/1.3, copper, mesh 300 grids with 2 nm amorphous carbon layer on top were glow discharged for 30 s at 15 mA (EMS-100 Glow Discharge System, Electron Microscopy Sciences). Three microliters of a 140 nM mitoribosome sample was applied on the grid and incubated for 30 s at 100% humidity and 4°C. Variable blot times with Whatman #1 filter paper were used to control the ice thickness. Samples were vitrified with an FEI Vitrobot Mark IV (Thermo Fisher).

Cryo-EM data processing

The dataset was collected with an FEI Talos Arctica electron microscope (200 kV, Thermo Fisher, UCSF cryo-EM core facility) using a nine-show beam image-shift approach with coma compensation. The image stacks were collected in non-super-resolution mode, binned by a factor of 2, motion corrected, and dose-weighted using UCSF motioncor2 [30]. Dose-weighted micrographs were used to determine contrast transfer function parameters using CTFFIND 4.0 in cryoSPARC [31]. Template picker was used to pick particles corresponding

to mitoribosomes. The structure 7L08 [32] was used to generate a reference map in order to generate 2D classes that were used as input for the template picker. Particles were extracted with a box size of 560 pixels (twice the largest dimension of mitoribosome in 7L08). These particles were used for 2D classification. Only classes that clearly contained ice were omitted. Homogeneous refinement was carried out in cryoSPARC using the particles corresponding to the good classes, followed by nonuniform refinement, with both global CTF and defocus refinements turned on [33].

Atomic model building and structure refinement

The refined and sharpened map obtained after nonuniform refinement in cryoSPARC was used for model building in Coot [34]. Restraints for LZD were generated using eLBOW [35] within Phenix [36]. Model refinement was performed through multiple rounds of manual model building and real space refinement in Phenix [36]. We used OPLS3e/VSGB2.1 force field parameters in combination with phenix.real_space_refine to improve the ligand model [37]. This approach allows a more accurate assignment of partial charges to the small molecules compared to manual restraint generation. We used standard Phenix restraints for the macromolecule, while OPLS3e/VSGB2.1 force field was used to generate the restraints for LZD. We first prepared apo ribosome and LZD separately in Maestro prepwizard and then recombined them. The restraints for LZD that were generated using Maestro and the recombined complex were used as input for Phenix.real_space_refine. The protein residues and nucleotides of the 16S rRNA showed well-defined geometrical parameters (Supplementary Table S4). The figures were prepared using PyMOL Molecular Graphics System version 3.0.2 [38].

Results

CHL and LZD alter the distribution of mitoribosomes along transcripts

We used mitoribosome profiling as an unbiased approach to interrogate the position of mitoribosomes along transcripts with codon-level resolution [15]. In this technique, mitoribosomes from actively translating cells are isolated, RNase treatment is used to digest the RNA not protected by the ribosomes, and the remaining mitoribosome-protected footprints are sequenced and mapped to the mitochondrial genome. We performed mitoribosome profiling and total RNA sequencing in HEK293 suspension cells subjected to brief (5 min) treatment with 300 μ M CHL or LZD (or DMSO as a control). To minimize artifacts from post-treatment effects, we collected the cells using flash filtration and rapid freezing in liquid nitrogen.

Treatment with CHL or LZD led to distinct changes in ribosomal distribution along the length of each of the 11 mitochondrial transcripts (Fig. 1B), although the relative coverage between transcripts was unaltered for most transcripts (Fig. 1B). Relative ribosomal occupancy, defined as codon-level RPM, was directly correlated between CHL- and LZD-treated cells (Supplementary Fig. S1A, Pearson r 0.588–0.768), but distinct from DMSO-treated cells (Supplementary Fig. S1B, Pearson r 0.348–0.542). Cells treated with CHL or LZD had more sites with high relative ribosomal occupancy (≥ 1000 RPM) as compared to the DMSO controls (Fig. 1D). Although

many of these sites were located near the start of mitochondrial transcripts, the profiles of CHL- and LZD-treated samples were distinct from those of cells treated with the translation initiation inhibitor RET (Fig. 1B and Supplementary Fig. S1B, Pearson r 0.295–0.502), indicating that CHL and LZD are inhibiting translation elongation rather than initiation.

If CHL and LZD were inhibiting translation elongation generically, the distribution of ribosomes in cells treated with these antibiotics should parallel the distribution of untreated cells. The altered distribution observed therefore argues against such a general mechanism and suggests that inhibition of mitoribosomal translation by CHL and LZD is contextually mediated. Ribosome profiling as performed, however, is unable to determine kinetic rate constants for chain elongation. Therefore, we are unable to rule out sequence-independent effects on translational elongation rates.

CHL and LZD show evidence of sequence-specific stalling

To investigate factors mediating antibiotic-induced translational inhibition, we examined ribosome occupancy at the individual codon level. Codon positional occupancy analysis of samples treated with CHL or LZD compared to DMSO controls revealed that the majority of predictive information was contained in the $P - 1$ position (Fig. 2A). Most distinctively, there was a pronounced bias toward alanine in the $P - 1$ position in antibiotic-treated samples. Alanine was present in the $P - 1$ position in roughly a quarter of ribosomal footprints in CHL- and LZD-treated cells (22% and 25%, respectively), as opposed to only 7.1% in DMSO-treated cells. Serine and threonine were also overrepresented, to a lesser extent, in the $P - 1$ position (CHL: 14% S, 12% T; LZD: 11% S, 18% T; DMSO: 7.0% S, 7.6% T) (Fig. 2B). These biases are consistent with those reported from ribosome profiling performed in bacteria [7]. Gly was also enriched in the $P - 1$ position of CHL-treated, but not LZD-treated cells (DMSO: 5.1%; CHL: 8.6%; LZD: 2.9%). The bias toward A/S/T/(G) in the $P - 1$ position was not codon-specific (Fig. 2C), indicating that causative effects are mediated by the amino acid incorporated into the nascent chain, rather than by the corresponding codon or tRNA. Furthermore, although the overall relative ribosome occupancy across most transcripts was unaffected by LZD or CHL treatment (Fig. 1C), ND6, which had increased occupancy upon LZD and CHL treatment, had a greater than average frequency of Ala codons (Supplementary Table S3). Conversely, ND4L, which had decreased occupancy upon treatment, had a lower than average frequency of Ala codons. This could be attributable, in part, to differences in stalling.

Although a $P - 1$ alanine was the strongest predictor of stalling, not all instances of alanine led to stalls. Therefore, we further investigated secondary mediators. Our analysis of all footprints revealed an underrepresentation of glycine in the P and $P + 1$ (A) positions in antibiotic-treated cells (Fig. 2D). Gly was present in the P position of footprints 6.2% of the time in DMSO-treated cells, but only 3.6% and 2.9% of footprints in cells treated with CHL or LZD, respectively. Similar decreases in Gly abundance were seen in the $P + 1$ position: 5.4% in DMSO-treated cells, compared to 2.4% in CHL-treated cells, and 3.9% in LZD-treated cells. Pairwise analysis of $P - 1:P$ and $P - 1:P + 1$ positions revealed that, with CHL, Gly in either the P or the $P + 1$ site appears to alleviate pausing asso-




Figure 3. LZD and CHL treatment leads to increased, and biased, ribosomal pausing. **(A)** Number of pause sites, defined as codons where the ribosomal RPM is >2 -fold over the mean RPM in a 21-codon sliding window in cells treated with CHL, LZD, or DMSO. **(B)** kpLogo [22] probability logo of stall site sequences reveals a large $P - 1$ A/S/T bias in stall sites of LZD- and CHL-treated cells (left and middle) that is absent in those of DMSO-treated cells (right), which are much more heterogeneous. Background was taken as the average across all positions in input sequences. Y axis represents statistical significance determined by one-sided binomial tests of each residue at each position; enriched residues stack on the top, whereas depleted residues stack on the bottom. LZD: linezolid; CHL: chloramphenicol; DMSO: dimethyl sulfoxide.

ciated with Ala in the $P - 1$ site, although the effect is more pronounced with Gly in the $P + 1$ site (Supplementary Fig. S2A and B). With LZD, Gly in P site, but not Gly in the $P + 1$ site, appears to alleviate such pausing (Supplementary Fig. S2C and D). Alleviation of stalling by glycine in the P or $+1$ position is consistent with observations from bacterial systems [7, 8]. The lack of steric hindrance of a tRNA-bound nascent peptide containing Gly at its C-terminus and the small size of Gly as an incoming nucleophile have been proposed to allow for peptidyl transfer even in the presence of nascent peptide-stabilized, PTC-bound antibiotic [8, 9].

To better understand sequence features of nascent peptides that cause the greatest inhibition of mitochondrial translation in the presence of each antibiotic, we next focused our analysis on the most prominent stalling sites. For this purpose, we defined “stall sites” as codons where the ribosomal RPM was >2 -fold over the mean RPM in a seven-codon sliding window ($n = 5$ datasets for CHL, 6 for LZD, and 4 for DMSO). Using this criterion, we identified 321 stall sites in CHL-treated cells, 313 stall sites in LZD-treated cells, and 168 stall sites in DMSO-treated cells (Fig. 3A).

Alanine was the most prominent amino acid present in the $P - 1$ position of these stall sequences (35% of LZD stall sites and 28% of CHL stall sites), followed by threonine (25% in LZD, 15% in CHL) and serine (17% in LZD, 23% in CHL) (Fig. 3B). These values were much higher than those found in DMSO stall sites (8% A, 3% T, 6% S), which were similar to those expected by chance (7% A, 7% S, 9% T). These values must be interpreted cautiously, however, due to the limited numbers of potential sequences. When we reanalyzed published mitoribosomal profiling datasets from HeLa cells treated with CHL [15], we found a highly similar stalling profile (Supplementary Fig. S3).

In vitro reconstitution validates critical role of -1 amino acid in translation inhibition

To evaluate the ability of CHL and LZD to directly cause sequence-specific stalling of mitoribosomes, we performed *in vitro* translation in a fully reconstituted mitochondrial translation system [39]. This system allows us to probe the dependence of stalling on specific amino acid residues within

the nascent chain and test the ability of our mitoribosome profiling to accurately identify mitoribosome stalling directly caused by antibiotics. To this end, we designed a split nLuc assay with a reporter transcript consisting of a putative stall sequence followed by an 11-amino acid HiBiT peptide [40, 41] (Fig. 4A). In the presence of the complementary LgBiT protein, active nLuc is formed, leading to the production of luminescence when supplied with an appropriate substrate. The short length of the HiBiT, as well as the lack of alanines in the sequence, minimizes the chance of antibiotic-induced stalling during its translation (Supplementary Table S1). This allows luminescence to serve as a readout of translation of the preceding test sequence. Furthermore, in order to minimize potential tRNA-dependent artifacts, we used human *in vitro* transcribed tRNAs for incorporation of the P and $P + 1$ (A-site) amino acids in the test sequence (Supplementary Table S2).

For a test sequence, we chose a mitochondrial stall site near the beginning of ND-6, MMYALF ($P - 1$ site underlined). This site had median pause scores (fold change over the mean of a 21-codon window; see the ‘Materials and methods’ section) of 11 in LZD-treated cells and 14 in CHL-treated cells, as compared to only 5 in DMSO-treated cells (Fig. 4B). It also contained only a single A/S/T residue, which would allow for unambiguous interpretation of results, and had a sequence that was compatible with current limitations in the *in vitro* aminoacylation of human mitochondrial tRNAs. Both CHL and LZD inhibited translation of the MMYALF reporter in a concentration-dependent manner, with IC_{50} values of 13 μ M (95% confidence interval 9.5–17 μ M) for CHL (Fig. 4C) and 38 μ M (30–47 μ M) for LZD (Fig. 4D). This inhibition was strongly dependent on the identity of the amino acid in the $P - 1$ position; changing the $P - 1$ alanine to a tyrosine led to a nearly eight-fold increase in the IC_{50} of CHL [99 μ M (70–125)], and increased the IC_{50} of LZD to >500 μ M (Fig. 4C and D).

These results further support that CHL and LZD do not act as general elongation inhibitors; rather, the ability of these antibiotics to inhibit translation is dependent on the amino acids in the sequence that is being translated. Furthermore, these data validate the ability of our mitoribosomal profiling data analysis to identify sequences conducive to CHL- and LZD-induced stalling. *In vivo*, mitoribosomes associate with




Figure 4. A stall site identified by mitoribosome profiling produces sequence-specific stalling by CHL and LZD in a mitochondrial *in vitro* translation system. **(A)** Schematic of HiBiT-based reporter assay. **(B)** Box and whisker plot of pause scores (fold changes over the mean of a 21-codon window, see the ‘Materials and methods’ section) for the ND6 sequence MMYALF ($P - 1$ site underlined). The dotted line at 2 shows the cutoff for pause calling. Both LZD **(C)** and CHL **(D)** robustly inhibited translation of the identified stall sequence MMYALF in a dose-dependent manner. Significantly weaker inhibition was seen when the $P - 1$ position (underlined and bolded in panel A) was changed from an alanine to a tyrosine, consistent with the A/S/T bias observed through mitoribosome profiling. Luminescence values are plotted relative to DMSO control. Error bars indicate standard error of the mean (SEM). $n = 3$ technical replicates.

the insertase OXA1L and cotranslationally insert the nascent peptide into the inner mitochondrial membrane after it exits the ribosome [42]. Our *in vitro* translation system does not recapitulate this context, which could alter the dynamics of antibiotic-induced stalling; however, given that the antibiotic binding occurs in the PTC, distal to, and shielded from, the membrane, we do not anticipate such factors to have a large influence [42]. The luminescent readout only informs on extent of inhibition and not location of stalled ribosomes; however, in combination with the profiling data, these *in vitro* translation assay results are consistent with a model in which an alanine in the $P - 1$ position facilitates CHL- and LZD-induced mitoribosomal stalling.

The structure of the human mitoribosome bound to LZD reveals a highly conserved binding mechanism

The above model is consistent with observations made in bacterial ribosome inhibition, where the nascent peptide contributes to the formation of an antibiotic binding site within the ribosome [7–10]. The nascent peptide-dependent antibiotic binding in bacteria is a consequence of steric accommodation, as well as stabilizing interactions between the antibiotic and the amino acid residue in the $P - 1$ position. More specifically, the sequence of the nascent chain shapes the antibiotic binding site, with the $P - 1$ amino acid residue either

occluding (in the case of large amino acids) or forming stabilizing interactions (in the case of A/S/T) with the antibiotic. In contrast, little is known about binding mode of these antibiotics to mitochondrial ribosomes, apart from cross-linking of a photoactivatable LZD derivative implicating a similar binding site in the PTC [6].

We purified 55S mitoribosomes (mitomonosomes) from FreeStyle™ 293-F cells (HEK293 cells adapted for serum-free suspension culture) subjected to a brief, high concentration treatment with linezolid [5 min at 100 μg/μl (300 μM)] (see the ‘Materials and methods’ section). We verified the assembly of the 55S mitoribosome through 2D classification (Supplementary Fig. S4). Upon 3D reconstruction, we observed significant disordering and/or dissociation of the small (28S) subunit (mt-SSU) relative to the large (39S) subunit (mt-LSU). Since cross-linking data [6] and homology to the bacterial ribosome suggest that LZD binds in the PTC in the mitochondrial LSU, we proceeded with data collection and processing, determining a 2.62 Å cryo-EM structure of the LSU of the human mitoribosome bound to LZD (Supplementary Figs S5 and S6, and Supplementary Table S4). The density in the PTC is particularly well resolved, permitting the modeling of the conformation of the drug and surrounding solvent molecules.

To determine how the mitoribosome binds to LZD, we compared our LZD-bound structure to a previously determined

apo mitoribosome (PDB 7QI5 [28]) (Fig. 5B). As expected, the conformations of most of the nucleotides in the PTC were unperturbed by LZD. A notable exception is U2993 of the 16S rRNA, whose ribose is shifted away to accommodate the bulky fluorophenyl B ring of LZD, avoiding a clash (Fig. 5B). We also observe density consistent with a metal, likely Mg^{2+} , that is coordinated, in part, by the oxazolidinone moiety of the antibiotic (Fig. 5B). Both of these features are consistent with the features observed in our previous structures of the *E. coli* ribosome bound to LZD alone (PDB 7S1H) and LZD with a stalled peptide (PDB 7S1G): the analogous base (U2506 in *E. coli*) shifts to accommodate LZD and a metal binds the oxazolidinone ring with similar geometry [10].

To directly compare the bacterial and mitochondrial binding modes, we aligned the mitoribosome–LZD complex to the structure of the *E. coli* LZD-stalled ribosome complex (PDB 7S1G) using the LZD A, B, and C ring atoms (root mean square deviation (RMSD) 0.48 Å) (Fig. 5C). In *E. coli* ribosomes, the density supporting the conformation of the C5 tail of LZD was stronger for the stalled complex than the otherwise empty ribosome; nevertheless, we observe strong density supporting modeling of the C5 tail conformation of the mitoribosome complex even in the absence of a nascent chain. In the mitoribosome, the conformation of the LZD C5 tail moves 2.2 Å away from the position observed in the stalled *E. coli* complex. In addition, a torsional change repositions the amide carbonyl group of the C5 tail to face where the putative nascent chain would be located. Although, as expected due to dissociation of the SSU, we do not observe any density for a nascent chain in the mitoribosome complex, we do observe strong density for solvent molecules hydrogen bonded to the amide moiety of the C5 tail. In addition, the twisted conformation of the C5 tail alters the “binding pocket” for the nascent peptide. Its pivot away may explain the relaxed specificity for accommodating the bulkier Thr residue in the $P - 1$ position for the mitochondrial ribosome compared to *E. coli* (Fig. 5C). Expanded room in the PTC of the mitoribosome compared to bacterial ribosomes may also help explain increased incidence of Cys and Val, at the $P - 1$ site at mitoribosomal CHL/LZD stall sites (Fig. 5C and Supplementary Table S3). The conformational preference of the C5 tail may be driven by the changes in solvation patterns observed between the two ribosomes. Despite worse global resolution for our mitoribosome–LZD complex (2.62 Å) compared to our previous LZD–*E. coli* ribosome complex (2.35 Å), we observed stronger density for solvent molecules throughout the PTC of the mitoribosome (Fig. 5D and Supplementary Fig. S7). This suggests that the ability of the C5 tail of LZD to interact with nascent chains may differ when bound in the two PTCs, and indicates that considering solvent interactions could provide an important selectivity handle in the design of oxazolidinone derivatives with reduced mitoribosome toxicity.

Discussion

The use of CHL and oxazolidinone antibiotics as antibacterial therapies has been limited by host mitotoxicity caused by off-target inhibition of mitochondrial translation [4, 43]. For example, LZD treatment is frequently discontinued due to reversible hematologic abnormalities [44–46]. Here, through mitoribosome profiling and *in vitro* translation assays, we show that these antibiotics cause context-specific stalling of mitoribosomes along transcripts in a manner consistent with

their effects on bacterial ribosomes. Together with our cryo-EM analysis of the human mitoribosome bound to LZD, these results provide critical insights into mode of inhibition of the mitoribosome by LZD, and may help inform the development of rationally designed next-generation oxazolidinone antibiotics. Such antibiotics are in increasingly high demand as global levels of antimicrobial resistance rise [1].

Our mitoribosome profiling data revealed that mitoribosomes become strongly, and reproducibly, stalled at discrete locations along each transcript in the presence of CHL and LZD (Fig. 1). Examination of these locations revealed a strong bias toward the presence of an alanine (and to a lesser extent serine or threonine) in the -1 position with respect to the P site, as well as a bias against glycine in the P and $P + 1$ (A) sites (Fig. 2) [6]. We were able to recapitulate antibiotic-dependent stalling at one such identified site in a fully reconstituted *in vitro* mitochondrial translation system (Fig. 4). We further confirmed the importance of the $P - 1$ amino acid for this stalling, as substitution of a $P - 1$ alanine to a tyrosine dramatically decreased the ability of LZD and, to a lesser but still significant extent, CHL, to inhibit translation of this sequence. In bacteria, this is due to mutually exclusive binding of antibiotic and a large amino acid at the $P - 1$ site [7–9]. Our findings indicate a mechanism of inhibition for CHL/LZD-mediated mitoribosome stalling consistent with that observed in bacteria, whereby the identity of the $P - 1$ amino acid determines whether the antibiotic can bind to the PTC.

Our reanalysis of published mitoribosomal profiling datasets from human cells treated with CHL identified a highly similar stalling profile (Supplementary Fig. S3). This is in contrast to a recent manuscript reporting a lack of sequence bias caused by CHL in mitoribosome profiling experiments [47]. In the said study, however, CHL was only included in the lysis buffer. This is in contrast to our experimental design, in which cells were pretreated with CHL prior to harvesting. Given the inefficiency of mitochondrial translation and the extreme dilution upon lysis, lack of pretreatment could account for the apparent discrepancy. While our manuscript was under review, an additional study reported stalling preferences similar to those we observed for both CHL and LZD in HEK cells [48].

In bacterial ribosome profiling, a stronger alanine bias was found in LZD- compared to CHL-treated cells, with serine and threonine showing increased representation in the $P - 1$ position in CHL-treated as opposed to LZD-treated cells [7]. This was attributed to the presence of an additional nascent peptide–antibiotic interaction between the hydroxyl group of threonine (and presumably serine) and one of CHL's chlorines [9]. Our mitoribosome profiling similarly showed a stronger alanine bias in the $P - 1$ position in LZD- compared to CHL-treated cells (Fig. 2B); however, we saw relatively increased representation of serine and threonine in the LZD-treated cells compared to the bacterial findings. This Thr enrichment in LZD-treated cells suggests that there may be subtle differences in the binding interactions between the nascent chain and LZD in mitochondrial ribosomes compared to bacterial ribosomes, as suggested by altered conformation of the C5 tail of the antibiotic in bacterial ribosomes versus mitoribosomes (Fig. 5).

To investigate the structural basis of context-dependent stalling of mitoribosomes, we obtained the cryo-EM structure of the LSU of the human mitoribosome bound to LZD (Fig. 5). Comparison with LZD bound to a bacterial ribosome re-




Figure 5. Structure of the large (39S) subunit of the human mitochondrial ribosome (mt-LSU) in complex with LZD shows strong water density in the PTC and an ordered C5 side chain. **(A)** Chemical structure of LZD, with key structural features indicated. The oxazolidinone (A) ring, characteristic of oxazolidinone antibiotics, is shown in bold. **(B)** Structure of LZD in the mt-LSU (present paper, green) compared to the apo mitoribosome (PDB 7QI5 [28], yellow). LZD clashes with the ribose of U2993 of the 16S rRNA in the apo structure, necessitating a conformational adjustment. Metal ion, assigned as Mg^{2+} , interacts with the carbonyl oxygen of the A ring and ribosomal RNA. **(C)** Overlay of the mitoribosome-bound LZD (this paper, green) and the stalled complex of LZD and a nascent chain on the *E. coli* ribosome (PDB 7S1G [10]: bacterial ribosome nucleotides, cyan; and nascent chain, purple). The C5 tail conformation is altered by displacement and a torsional change that displays the amide carbonyl toward the nascent chain. A threonine residue has been modeled in place of the alanine present in the nascent chain observed in the structure in order to demonstrate the possible accommodation of the bulkier residue in the mitoribosomal structure given the altered C5 conformation. A hydrogen bond of the carbonyl group of the amide to a solvent molecule (blue sphere) is indicated by dashed lines. **(D)** Density for solvent molecules in the LZD-bound PTC of the mitoribosome observed at 3.8σ . No solvent molecule density is observed in the LZD-bound structure of the *E. coli* ribosome (PDB 7S1H, magenta) at 2.2σ , which equivalently encompasses the surrounding bases, LZD, and a metal ion, assigned as Mg^{2+} .

vealed that the binding of LZD to mitoribosomes is similar to its binding to bacterial ribosomes, with notable differences in the conformation of the C5 tail and the extent of solvation in the PTC when LZD is bound (Fig. 5). The altered conformation of the tail may underlie the higher amount of stalling on Thr observed for the mitochondrial ribosome relative to the *E. coli* ribosome. Resolving a stalled complex of a Thr-containing nascent peptide chain stalled on the mitoribosome will be needed to dissect the structural basis of this change in specificity. The unique features of mitochondrial translation and the extensive process of mitoribosome purification, however, present steep challenges to its ascertainment.

Our present structure can inform strategies for widening the selectivity window between bacterial ribosomes and mitoribosomes, which is one of the barriers limiting the wider clinical use of oxazolidinone antibiotics. Increased solvation of the PTC region of the mitoribosome, as compared to the *E. coli* ribosome, influences the conformation of the C5 tail of LZD. Importantly, the ordering of water goes against expectation based on the global resolution of the density maps: the higher-resolution *E. coli* map has fewer ordered waters.

Collectively, these results point to the importance of considering solvation in tuning selectivity for highly conserved binding sites [49, 50].

In summary, our findings indicate that inhibition of mitoribosome translation by CHL and LZD antibiotics occurs in a nascent peptide sequence-selective manner, a feature conserved with inhibition of the bacterial ribosome by these compounds. Our study lays the groundwork for future, targeted, investigation into selectivity and mitotoxicity of oxazolidinone compounds and provides a high-resolution structure of the binding site of linezolid on the human mitoribosome that can serve as a valuable resource in the design of next-generation antibiotics.

Limitations of this study

In this work, we carried out mitoribosome profiling in a single cell type, FreeStyle™ 293-F. We uncovered evidence of similar CHL-associated mitotranslational biases in an independent dataset collected in HeLa cells [15] (Supplementary Fig. S3); however, future studies in additional cell types will be needed

in order to determine the broader generalizability of our findings, especially with regard to LZD, for which no other mitoribosome profiling data are available for comparison. Nevertheless, the ability to recapitulate an identified stall site in a fully reconstituted system indicates that the core translational machinery is sufficient to mediate the observed context-specificity. Due to current technical limitations of the *in vitro* translation system, we were unable to further interrogate the determinants of mitoribosomal stalling, including the ability of a glycine in the *P* and/or *P* + 1 positions to overcome stalling. Human mt-tRNAs have distinctive structures [51, 52] and many, including that for glycine, pose currently insurmountable challenges to *in vitro* transcription and aminoacylation. This highly restricts the choice of test sequences for the HiBiT assay. Advances in the reconstituted transcription and translation systems, namely the ability to generate and aminoacylate all human mt-tRNAs, could allow for testing additional sequences to further investigate our proposed model.

We chose the concentrations and incubation times we used for footprinting based on published conditions from other experiments [7, 14, 15] and to optimize the chances of detecting differential effects of the treatment conditions on translation that might be masked by longer treatment times and/or higher concentrations. Although the concentrations of antibiotics we used [300 μ M (~100 μ g/ml)] were in line with those commonly used in the laboratory, they were well above levels cells are likely exposed to during the course of antibiotic treatment—reported serum LZD levels vary widely [53, 54], but in one study were found to average 13.4 μ g/ml [55]. Our treatment, however, was also much briefer than clinical courses of LZD treatment, which can last 6 months in the case of some drug-resistant tuberculosis [56]. Because such time frames are not amenable to tissue culture, we chose higher, but moderate, concentrations—thus ensuring that sufficient quantities of compounds could reach the mitochondrial matrix—along with a short time frame to limit the induction of stress-related responses that could compound the results and prevent complete translation inhibition. It is unknown how our results carry over to a lower-dose, longer-period, treatment time.

Additionally, we did not investigate any physiological effects of sequence-selective inhibition. The stall sites we observed through mitoribosome profiling were distributed over all transcripts (Fig. 1B). However, it is possible that, similarly to the distinct phenotypic effects of different mtDNA mutations, preferential stalling of specific transcripts could lead to distinctive respiratory chain imbalances.

Acknowledgements

We thank Stephen Floor, Albert Xu, and Yan Zhang for guidance with ribosome profiling; Giovanni Aviles for assistance with mitoribosome purification and mitoribosome profiling; and Daniel Hogan for help with data storage and transfers. We also thank Xiaoyang Guo and Mo Yao for assistance with *in vitro* translation assays and Isha Jain, Annia Rodriguez Hernández, Chloe Ghent, and Ada Álvarez Muñoz for helpful discussions.

Author contributions: B.B. conceived the research, designed and performed mitoribosome profiling and purification of mitoribosomes for structural characterization, analyzed data, and wrote the manuscript. T.R. performed structural analysis and assisted in manuscript writing. M.C. analyzed mitoribo-

some profiling data and assisted in manuscript writing. M.H. performed *in vitro* translation assays and assisted in data interpretation. J.I.K. assisted in experimental design, data interpretation, and manuscript editing. N.T. supervised the *in vitro* translation experiments, assisted in experimental design and data interpretation, and edited the manuscript. L.S.C. supervised the mitoribosome profiling data analysis, assisted in data interpretation, and edited the manuscript. J.S.F. supervised the structural analysis, assisted in experimental design and data interpretation, and assisted in manuscript writing. D.G.F. conceived and supervised the research, assisted in data interpretation, and edited the manuscript.

Supplementary data

Supplementary data is available at NAR online.

Conflict of interest

None declared.

Funding

We acknowledge support from the National Institute of Allergy and Infectious Diseases (NIAID) (R01AI137270 to D.G.F.), National Institute of General Medical Sciences (NIGMS) (R01GM123002 to L.S.C.), the W.M. Keck Foundation Medical Research Grant (to J.S.F. and D.G.F.), the University of California, San Francisco Discovery Fellowship (to J.I.K.), and Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) (23H04252 to N.T.). Funding to pay the Open Access publication charges for this article was provided by NIAID (R01AI137270 to D.G.F.).

Data availability

Atomic coordinates for the structure of the human mitochondrial ribosome large subunit (39S) bound to linezolid have been deposited in the PDB under the accession number 9CN3 and the EMDB under the accession number EMD-45757. Raw and processed sequencing data were deposited in the GEO database under the accession number GSE273206. Processing and analysis scripts are available at Zenodo under DOI: 10.5281/zenodo.14590510 [23]; an add-on to DOI: 10.5281/zenodo.6814724 [24].

References

- Centers for Disease Control and Prevention *Antibiotic Resistance Threats in the United States*, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC, 2019. <https://www.cdc.gov/antimicrobial-resistance/data-research/threats/index.html>
- Negatu DA, Aragaw WW, Cangialosi J *et al.* Side-by-side profiling of oxazolidinones to estimate the therapeutic window against mycobacterial infections. *Antimicrob Agents Chemother* 2023;67:e0165522. <https://doi.org/10.1128/aac.01655-22>
- Soriano A, Miró O, Mensa J. Mitochondrial toxicity associated with linezolid. *N Engl J Med* 2005;353:2305–6. <https://doi.org/10.1056/NEJM200511243532123>
- Garrahou G, Soriano A, López S *et al.* Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. *Antimicrob Agents Chemother* 2007;51:962–7. <https://doi.org/10.1128/AAC.01190-06>

5. De Vriese AS, Van Coster R, Smet J *et al.* Linezolid-induced inhibition of mitochondrial protein synthesis. *Clin Infect Dis* 2006;42:1111–7. <https://doi.org/10.1086/501356>
6. Leach KL, Swaney SM, Colca JR *et al.* The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. *Mol Cell* 2007;26:393–402. <https://doi.org/10.1016/j.molcel.2007.04.005>
7. Marks J, Kannan K, Roncase EJ *et al.* Context-specific inhibition of translation by ribosomal antibiotics targeting the peptidyl transferase center. *Proc Natl Acad Sci USA* 2016;113:12150–5. <https://doi.org/10.1073/pnas.1613055113>
8. Choi J, Marks J, Zhang J *et al.* Dynamics of the context-specific translation arrest by chloramphenicol and linezolid. *Nat Chem Biol* 2020;16:310–7. <https://doi.org/10.1038/s41589-019-0423-2>
9. Syroegin EA, Flemmich L, Klepacki D *et al.* Structural basis for the context-specific action of the classic peptidyl transferase inhibitor chloramphenicol. *Nat Struct Mol Biol* 2022;29:152–61. <https://doi.org/10.1038/s41594-022-00720-y>
10. Tsai K, Stojković V, Lee DJ *et al.* Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics. *Nat Struct Mol Biol* 2022;29:162–71. <https://doi.org/10.1038/s41594-022-00723-9>
11. Wilson DN, Schlutzen F, Harms JM *et al.* The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. *Proc Natl Acad Sci USA* 2008;105:13339–44. <https://doi.org/10.1073/pnas.0804276105>
12. Greber BJ, Ban N. Structure and function of the mitochondrial ribosome. *Annu Rev Biochem* 2016;85:103–32. <https://doi.org/10.1146/annurev-biochem-060815-014343>
13. McKee EE, Ferguson M, Bentley AT *et al.* Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. *Antimicrob Agents Chemother* 2006;50:2042–9. <https://doi.org/10.1128/AAC.01411-05>
14. Almeida L, Dhillon-LaBrooy A, Castro CN *et al.* Ribosome-targeting antibiotics impair T cell effector function and ameliorate autoimmunity by blocking mitochondrial protein synthesis. *Immunity* 2021;54:68–83. <https://doi.org/10.1016/j.immuni.2020.11.001>
15. Soto I, Couvillion M, Hansen KG *et al.* Balanced mitochondrial and cytosolic translational underlie the biogenesis of human respiratory complexes. *Genome Biol* 2022;23:170. <https://doi.org/10.1186/s13059-022-02732-9>
16. McGlincy NJ, Ingolia NT. Transcriptome-wide measurement of translation by ribosome profiling. *Methods* 2017;126:112–29. <https://doi.org/10.1016/j.jmeth.2017.05.028>
17. Ingolia NT, Brar GA, Rouskin S *et al.* The ribosome profiling strategy for monitoring translation *in vivo* by deep sequencing of ribosome-protected mRNA fragments. *Nat Protoc* 2012;7:1534–50. <https://doi.org/10.1038/nprot.2012.086>
18. Jowhar Z, Xu A, Venkataramanan S *et al.* A ubiquitous GC content signature underlies multimodal mRNA regulation by DDX3X. *Mol Syst Biol* 2024;20:276–90. <https://doi.org/10.1038/s44320-024-00013-0>
19. Park J, Desai H, Liboy-Lugo JM *et al.* IGHMBP2 deletion suppresses translation and activates the integrated stress response. *Life Sci Alliance* 2024;7:e202302554. <https://doi.org/10.26508/lsa.202302554>
20. Soto I, Couvillion M, Stirling Churchman L. Human mitoribosome profiling: a re-engineered approach tailored to study mitochondrial translation. In: Barrientos A, Fontanesi F (eds.), *The Mitoribosome: Methods and Protocols*. New York, NY: Springer US, 2023, 257–80.
21. Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. *Nucleic Acids Res* 2019;47:e47. <https://doi.org/10.1093/nar/gkz114>
22. Wu X, Bartel DP. kpLogo: positional *k*-mer analysis reveals hidden specificity in biological sequences. *Nucleic Acids Res* 2017;45:W534–8. <https://doi.org/10.1093/nar/gkx323>
23. Couvillion M. human-mitoribosome-profiling_appendixA. Zenodo. <https://doi.org/10.5281/zenodo.14590510>. 2025.
24. mtcouvi. churchmanlab/human-mitoribosome-profiling. v1.0.0. Zenodo. <https://doi.org/10.5281/zenodo.6814724>. 2022.
25. Nagai R, Xu Y, Liu C *et al.* *In vitro* reconstitution of yeast translation system capable of synthesizing long polypeptide and recapitulating programmed ribosome stalling. *Methods Protoc* 2021;4:45. <https://doi.org/10.3390/mps4030045>
26. Lee M, Takeuchi-Tomita N. Reconstitution of mammalian mitochondrial translation system capable of long polypeptide synthesis. In: Barrientos A, Fontanesi F (eds.), *The Mitoribosome: Methods and Protocols*. New York, NY: Springer US, 2023, 233–55.
27. Aibara S, Andréll J, Singh V *et al.* Rapid isolation of the mitoribosome from HEK cells. *J Vis Exp* 2018;140:57877. <https://doi.org/10.3791/57877>
28. Singh V, Itoh Y, Del'Olivo S *et al.* Mitoribosome structure with cofactors and modifications reveals mechanism of ligand binding and interactions with L1 stalk. *Nat Commun* 2024;15:4272. <https://doi.org/10.1038/s41467-024-48163-x>
29. Yang H, Desai N. Purification of mitochondrial ribosomes with the translocase Oxa1L from HEK cells. *Bio Protoc* 2021;11:e4110. <https://doi.org/10.21769/BioProtoc.4110>
30. Zheng SQ, Palovcak E, Armache J-P *et al.* MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* 2017;14:331–2. <https://doi.org/10.1038/nmeth.4193>
31. Punjani A, Rubinstein JL, Fleet DJ *et al.* cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat Methods* 2017;14:290–6. <https://doi.org/10.1038/nmeth.4169>
32. Koriella RK, Deep A, Agrawal EK *et al.* Distinct mechanisms of the human mitoribosome recycling and antibiotic resistance. *Nat Commun* 2021;12:3607. <https://doi.org/10.1038/s41467-021-23726-4>
33. Punjani A, Zhang H, Fleet DJ. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. *Nat Methods* 2020;17:1214–21. <https://doi.org/10.1038/s41592-020-00990-8>
34. Emsley P, Lohkamp B, Scott WG *et al.* Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* 2010;66:486–501. <https://doi.org/10.1107/S0907444910007493>
35. Moriarty NW, Grosse-Kunstleve RW, Adams PD. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. *Acta Crystallogr D Biol Crystallogr* 2009;65:1074–80. <https://doi.org/10.1107/S0907444909029436>
36. Adams PD, Afonine PV, Bunkóczi G *et al.* PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* 2010;66:213–21. <https://doi.org/10.1107/S0907444909052925>
37. Roos K, Wu C, Damm W *et al.* OPLS3e: extending force field coverage for drug-like small molecules. *J Chem Theory Comput* 2019;15:1863–74. <https://doi.org/10.1021/acs.jctc.8b01026>
38. DeLano WL. PyMOL: an open-source molecular graphics tool. *CCP4 NewslProtein Crystallogr* 2002;7 82–92.
39. Lee M, Matsunaga N, Akabane S *et al.* Reconstitution of mammalian mitochondrial translation system capable of correct initiation and long polypeptide synthesis from leaderless mRNA. *Nucleic Acids Res* 2021;49:371–82. <https://doi.org/10.1093/nar/gkaa1165>
40. Schwinn MK, Machleidt T, Zimmerman K *et al.* CRISPR-mediated tagging of endogenous proteins with a luminescent peptide. *ACS Chem Biol* 2018;13:467–74. <https://doi.org/10.1021/acscchembio.7b00549>
41. Dixon AS, Schwinn MK, Hall MP *et al.* NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. *ACS Chem Biol* 2016;11:400–8. <https://doi.org/10.1021/acscchembio.5b00753>

42. Itoh Y, Andréll J, Choi A *et al.* Mechanism of membrane-tethered mitochondrial protein synthesis. *Science* 2021;371:846–9. <https://doi.org/10.1126/science.abe0763>
43. Renslo AR. Antibacterial oxazolidinones: emerging structure–toxicity relationships. *Expert Rev Anti Infect Ther* 2010;8:565–74. <https://doi.org/10.1586/eri.10.26>
44. Wang MG, Wang D, He JQ. Reversible recurrent profound thrombocytopenia due to linezolid in a patient with multi-drug resistant tuberculosis: a case report. *Medicine* 2018;97:e11997.
45. La YJ, Kim YC. Successful treatment of vancomycin-resistant *Enterococcus* species bone and joint infection with daptomycin plus beta lactam agents. *Infect Chemother* 2022;54:797–802. <https://doi.org/10.3947/ic.2022.0106>
46. Sharma S, Syal A, Gupta M *et al.* Reversible myelosuppression with prolonged usage of linezolid in treatment of methicillin-resistant *Staphylococcus aureus*. *Cureus* 2020;12:e10890.
47. Wakigawa T, Mito M, Yamashiro H *et al.* Complexity and dynamics of in organello translation landscape assessed by high-resolution mitochondrial ribosome profiling. *bioRxiv*, <https://doi.org/10.1101/2023.07.19.549812>, 7 June 2024, preprint: not peer reviewed.
48. Marks J, Young E, Hafner M. Determining the off-target activity of antibiotics and novel translation initiation sites in mitochondria. *eLife* 2024;13:RP103699. <https://doi.org/10.7554/eLife.103699.1>
49. Beuming T, Farid R, Sherman W. High-energy water sites determine peptide binding affinity and specificity of PDZ domains. *Protein Sci* 2009;18:1609–19. <https://doi.org/10.1002/pro.177>
50. Robinson D, Bertrand T, Carry J-C *et al.* Differential water thermodynamics determine PI3K-beta/delta selectivity for solvent-exposed ligand modifications. *J Chem Inf Model* 2016;56:886–94. <https://doi.org/10.1021/acs.jcim.5b00641>
51. Suzuki T, Yashiro Y, Kikuchi I *et al.* Complete chemical structures of human mitochondrial tRNAs. *Nat Commun* 2020;11:4269. <https://doi.org/10.1038/s41467-020-18068-6>
52. Sissler M, Pütz J, Fasiolo F *et al.* Mitochondrial aminoacyl-tRNA synthetases. In: *Madame Curie Bioscience Database [Internet]*. Austin (TX): Landes Bioscience, 2013. <https://www.ncbi.nlm.nih.gov/books/NBK6033/>
53. Zoller M, Maier B, Hornuss C *et al.* Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. *Crit Care* 2014;18:R148. <https://doi.org/10.1186/cc13984>
54. Galar A, Valerio M, Muñoz P *et al.* Systematic therapeutic drug monitoring for linezolid: variability and clinical impact. *Antimicrob Agents Chemother* 2017;61:e00687–17. <https://doi.org/10.1128/AAC.00687-17>
55. Honeybourne D, Tobin C, Jevons G *et al.* Intrapulmonary penetration of linezolid. *J Antimicrob Chemother* 2003;51:1431–4. <https://doi.org/10.1093/jac/dkg262>
56. Thwaites G, Nguyen NV. Linezolid for drug-resistant tuberculosis. *N Engl J Med* 2022;387:842–3. <https://doi.org/10.1056/NEJMc2208554>